New
home-care electronic product measures arterial hardness, blood pressure and heart
rate
13 April, 2006, TAIPEI, Taiwan -- Taipei-based biomedical technology
company Formosa Biomedical Technology Corporation announced its readiness to market
its revolutionary new arterial hardness home healthcare diagnostic device to European
consumers. The company's Automatic Digital Blood Pressure
Monitor with Arterial Hardness Value Measurement is a three-in-one electronic
device utilizing medical technology previously available only to doctors in a
hospital setting. Using patented sensor technology, the device determines the
hardness of a person's arteries while simultaneously measuring blood pressure
and heart rate. Arterial
hardness is a symptom of arteriosclerosis, a condition where the body's arteries
thicken, harden and become slowly blocked over time due to life style, dietary
and genetic factors. Advanced arteriosclerosis can cause a number of serious health
problems, including cerebral hemorrhage and stroke, angina and heart attacks,
kidney disease and circulatory system breakdown in the limb extremities.
The device utilizes technology first invented in Japan and developed and perfected
in the Formosa Biomedical research facilities in Taiwan, into a novel, easy-to-use
home-care product.
"We have developed a product that lets you take
a closer look at your cardiovascular system. By determining your arterial hardness
level, you can uncover potential health problems that otherwise wouldn't be picked
up outside of a medical examination in a hospital," said Taylor Chang, Deputy
Manager of Formosa Biomedical's sales and marketing department. "We believe
that regular testing of arterial hardness is a simple and effective means of monitoring
and safeguarding your health. Our product allows you to do this at home, at your
convenience," he said. Dr. Err-Cheng Chan, Executive Vice President
of Formosa Biomedical and a Professor at Chang Gung University Medical School,
stated that most people underestimate the risk of undetected cardiovascular disease.
"Even when coronary blood vessels are narrowed by as much as 80 percent,
symptoms are not usually apparent to the affected person. However, roughly 60
percent of affected people die from their first heart attack," stated Chan.
What's
more troubling, said Chan, is that the death rate from heart attack victims with
no history of symptoms is twice as high as that of the general population of heart
attack victims, showing that identification and awareness of cardiovascular disease
symptoms is the key to surviving heart attacks. Formosa Biomedical introduced
the product at November, 2005's Medica exhibition in Germany--the world's largest
exhibition for the medical device equipment industry--to strong interest. Since
then, the company has been to looking to build up a network of qualified distributors
in Europe. Dr. Err-Cheng Chan, Executive Vice President of Formosa Biomedical
and a Professor at Chang Gung University Medical School, stated that most people
underestimate the risk of undetected cardiovascular disease. "We
are interested in working with distributors who understand the importance of vascular
system monitoring and are willing to assist in spreading the good news about this
revolutionary product," said Chang.
The Automatic Digital Blood
Pressure Monitor with Arterial Hardness Value Measurement has received FDA
and CE approval for its class of devices. Formosa Biomedical is interested in
receiving applications from all interested parties looking to become agents for
the product in European countries. Please enquire with Taylor Chang at the contact
numbers below. About Formosa Biomedical Technology Corporation.
Formosa Biomedical Technology Corporation was founded in 2004, with a
mission to develop and manufacture high-tech, high quality, safe and healthy products
by integrating three major resources of Formosa Group in manufacturing, academic
studies and clinical research and services. In the mean time, we wish to strengthen
our core competency and shape the company as an international brand on the basis
of our unique core technology, company culture and characteristics of products.
Our product line includes diagnostics devices, lab and research supplies, detergents
and cosmetics. The development of protein drugs and vaccine will also be our research
scope in the future. The company works closely with Formosa Group's Chang
Gung University and the Chang Gung Hospital, sharing resources such as research
facilities and the advice and expertise of its resident medical experts.
About
Formosa Group of companies Please visit the Formosa Group corporate website
at www.fpg.com.tw for information about the Formosa Group of companies.
Contact:
Taylor Chang Deputy Manager Sales & Marketing Department, Medical
Technology Division Formosa Biomedical Technology Corporation taylorchang@fpg.com.tw http://www.fbc.com.tw
Source:
Formosa Biomedical Technology Corporation Attached photo: Formosa Biomedical
Technology Corporation's new Automatic Digital Blood Pressure Monitor
with Arterial Hardness Value Measurement device
|